Article

B + L recalls dry eye drop

Bausch + Lomb (B+L) has voluntarily recalled one lot of a 1% methylcellulose lubricant ophthalmic solution (Murocel) after routine stability testing showed that its preservative was ?out of specification? for efficacy.

Madison, NJ-Bausch + Lomb (B + L) has voluntarily recalled one lot of a 1% methylcellulose lubricant ophthalmic solution (Murocel) after routine stability testing showed that its preservative was “out of specification” for efficacy.

No adverse events attributed to the issue have been reported, the company said, adding that potential adverse events could include eye pain, change in vision, redness or irritation of the eye, or ocular infection.

The over-the-counter eye drop has been available for more than a decade for the temporary relief of burning and irritation due to dry eye. It is sold only in the United States.

B + L has informed eye-care professionals of the recall and has told U.S. retailers how they can return the product. Consumers who have purchased the recalled eye drop should return it to B + L; they may call 800/553-5340 for instructions on how to do so and obtain reimbursement. The customer service line is available weekdays from 9 a.m. to 5 p.m. Eastern Time.

Details about the recalled solution:

Lot number: 507521
Expiration date: Jan. 31, 2012
UPC code: 3 24208 28015 7
Case code: (01)50324208280154(30)00144

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.